Sodium–glucose co-transporter 2 (SGLT2) inhibitors, which were developed as therapeutic agents for diabetes mellitus, have been used in the management of chronic kidney disease (CKD) and heart failure even in patients without diabetes [6]. The gene discussed is SLC5A2; the disease is chronic kidney disease.